Literature DB >> 8414864

Fluoxetine hydrochloride (Prozac) toxicity in a neonate.

M J Spencer.   

Abstract

A case of fluoxetine toxicity in a newborn of 38 weeks' gestation has been presented. The total drug concentration in cord blood was 80 ng/mL. The fluoxetine level, 26 ng/mL, is below the adult therapeutic level; the norfluoxetine cord blood level, 54 ng/mL, is at the adult therapeutic level. At 96 hours the fluoxetine level was not measurable and the norfluoxetine level was 55 ng/mL. The parent compound is fluoxetine, which is metabolized in the liver to norfluoxetine. The half-life of fluoxetine is 2 to 3 days, and that of norfluoxetine is 7 to 9 days. Interestingly, in our patient the fluoxetine was absent in the blood at 4 days, but norfluoxetine was present. The most common side effects of Prozac in adult patients involve primarily the central nervous system and include nervousness, tremor, jitteriness, and occasionally seizures. Central nervous system symptoms were most prominent in this newborn. He also had an increased heart rate. Cardiovascular side effects are less prominent in adults who are taking Prozac. The neonate in this case was asymptomatic at 96 hours of age, indicating that the parent compound, fluoxetine, may be the active part of the drug and side effects may be caused by the parent compound.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8414864

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  18 in total

1.  Paroxetine withdrawal in a neonate with historical and laboratory confirmation.

Authors:  Sanjay Jaiswal; Robert C Coombs; Geoffrey K Isbister
Journal:  Eur J Pediatr       Date:  2003-08-07       Impact factor: 3.183

Review 2.  Antidepressant use in pregnancy: a critical review focused on risks and controversies.

Authors:  N Byatt; K M Deligiannidis; M P Freeman
Journal:  Acta Psychiatr Scand       Date:  2012-12-14       Impact factor: 6.392

Review 3.  Treating mood disorders during pregnancy: safety considerations.

Authors:  Malin Eberhard-Gran; Anne Eskild; Stein Opjordsmoen
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 4.  Identifying genomic and developmental causes of adverse drug reactions in children.

Authors:  Mara L Becker; J Steven Leeder
Journal:  Pharmacogenomics       Date:  2010-11       Impact factor: 2.533

Review 5.  Serotonin reuptake inhibitor-induced perinatal complications.

Authors:  Salvatore Gentile
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 6.  Antidepressant use in pregnant and postpartum women.

Authors:  Kimberly A Yonkers; Katherine A Blackwell; Janis Glover; Ariadna Forray
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

Review 7.  Treating recurrent affective disorders during and after pregnancy. What can be taken safely?

Authors:  M Schou
Journal:  Drug Saf       Date:  1998-02       Impact factor: 5.606

8.  Are SSRIs safe for pregnant and breastfeeding women?

Authors:  S Misri; A Burgmann; D Kostaras
Journal:  Can Fam Physician       Date:  2000-03       Impact factor: 3.275

Review 9.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

10.  Nonepileptic motor phenomena in the neonate.

Authors:  Richard James Huntsman; Noel John Lowry; Koravangattu Sankaran
Journal:  Paediatr Child Health       Date:  2008-10       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.